TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

TG THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$53.30−0.67 (-1.24%)

Close on Oct 19, 2026

Market cap: $8.38B
P/E (TTM): 19.5
Dividend yield: –

TG THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	616	329	234	2.79	6.69	0.15	0.15	0.15	0.15	0.15	–	–	–	–	–	–
Cost of Revenue	101	38	14	0.27	0.79	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	516	291	220	2.52	5.90	–	–	–	–	–	–	–	–	–	–	–
Research & Development	160	94	76	125	223	166	154	159	103	69	48	40	14	21	0.33	–
Selling, General & Admin	232	154	123	95	128	108	15	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	108	15	15	16	9.89	16	16	6.66	4.78	0.55	–
Operating Expenses	–	–	–	196	351	274	169	175	119	79	63	56	23	27	0.88	–
Total Costs & Expenses	493	287	213	221	351	–	–	–	–	–	–	–	–	–	–	–
Operating Income	123	42	21	-218	-345	-274	-169	-174	-119	-79	-63	-56	-23	-27	-0.88	–
Interest Expense	27	24	13	10	5.64	6.33	5.29	0.88	0.85	–	0.97	0.93	0.95	0.91	0.01	–
Interest & Investment Income	–	–	–	–	–	–	–	0.86	0.30	0.32	0.17	0.06	0.03	–	–	–
Other Non-Operating Income	-16	-16	-7.57	-5.50	-3.33	-5.79	-3.82	0.92	0.24	0.72	0.23	-0.06	2.49	1.04	-0.01	–
Asset Impairment Charges	–	–	–	0	0	0	0	–	–	–	–	–	2.80	1.10	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	0	0	-0.03	0	0	–	–	–	–
Pretax Income	107	26	13	-224	-348	-0.28	-0.17	-0.17	-0.12	-78	-63	-56	-20	-26	-0.89	–
Income Tax Expense	-340	2.21	0.39	0	0	0	0	0	0	0	0	0	0	0.30	0	–
Net Income incl. Noncontrolling Interests	–	–	–	-198	-348	-279	-173	-173	-118	-78	-63	-56	-20	-26	-0.89	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	0	-8.11	-0.04	–
Net Income	447	23	13	-224	-348	–	–	–	–	–	–	–	-20	-18	-0.85	0.62
EPS (Basic)(per share)	3.10	0.16	0.09	-1.65	-2.63	-2.42	-1.96	-2.30	-1.91	-1.60	-1.38	-1.64	-0.81	-1.38	-0.44	–
EPS (Diluted)(per share)	2.77	0.15	0.09	-1.65	-2.63	-2.42	-1.96	-2.30	-1.91	-1.60	-1.38	-1.64	-0.81	-1.38	-0.44	–
Shares Outstanding (Basic, Weighted)(shares)	144	145	142	135	132	115	88	75	62	49	46	34	25	13	1.93	–
Shares Outstanding (Diluted, Weighted)(shares)	161	160	149	135	132	115	88	75	62	49	46	34	25	13	1.93	–
EBITDA	123	42	21	-218	-344	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 82.4%
Operating margin: 17.1%
Net margin: 55.2%
Return on equity, FY2025: 102.8%

Financial strength

Current ratio: 4.27
Debt to equity: 1.23
Debt to assets: 45.5%
Cash to current liabilities: 179.7%

Valuation

P/E ratio: 19.5
Price to sales: 10.48
Price to book: 13.88
Dividend yield: –